StemCyte, a leader in regenerative medicine, announced on March 2 the signing of a Memorandum of Understanding (MOU) with a major U.S. insurance brokerage to launch its world-first "Public Bank Protection Service" in the United States. This follows a successful 2025 rollout in Taiwan via Shinkong Life Insurance.

• Strategic Advantage: The cornerstone of this B2B model is StemCyte's REGENECYTE®, the only Taiwan-developed cell therapy product to receive U.S. FDA BLA approval. REGENECYTE® is indicated for nearly 80 hematological and immune-related disorders and is already eligible for insurance reimbursement in the U.S. at tens of thousands of dollars per dose.
• The Three-Arrow Strategy: StemCyte’s growth is anchored by its "Three Arrows": cell therapeutics (long-term), cell supply (mid-term CDMO focus), and cell services (short-term). The insurance-linked service model provides scalable, recurring revenue expected to show significant growth starting in Q2 2026.
• Public Listing: StemCyte received TWSE approval for its primary listing on January 20 and is scheduled to officially go public in Q2 2026.

Resource: 永笙創新公庫保障服務進軍國際 啟動美國市場布局